Cargando...
Alogliptin benzoate for management of type 2 diabetes
Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress glucagon levels through enhancement of the action of endogenous incretin by inhibiting DPP-4, an incretin-degrading enzyme. DPP-4 inhibitors are generally well...
Guardado en:
| Publicado en: | Vasc Health Risk Manag |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4401208/ https://ncbi.nlm.nih.gov/pubmed/25914541 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/VHRM.S68564 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|